129 related articles for article (PubMed ID: 12657921)
1. Sildenafil does not alter nelfinavir pharmacokinetics.
Bratt G; Ståhle L
Ther Drug Monit; 2003 Apr; 25(2):240-2. PubMed ID: 12657921
[TBL] [Abstract][Full Text] [Related]
2. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients.
Merry C; Barry MG; Ryan M; Tjia JF; Hennessy M; Eagling VA; Mulcahy F; Back DJ
AIDS; 1999 Oct; 13(15):F101-7. PubMed ID: 10546851
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir.
Muirhead GJ; Wulff MB; Fielding A; Kleinermans D; Buss N
Br J Clin Pharmacol; 2000 Aug; 50(2):99-107. PubMed ID: 10930961
[TBL] [Abstract][Full Text] [Related]
4. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
[TBL] [Abstract][Full Text] [Related]
6. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Goujard C; Legrand M; Panhard X; Diquet B; Duval X; Peytavin G; Vincent I; Katlama C; Leport C; Bonnet B; Salmon-Céron D; Mentré F; Taburet AM;
Clin Pharmacokinet; 2005; 44(12):1267-78. PubMed ID: 16372824
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
[TBL] [Abstract][Full Text] [Related]
8. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.
Washington CB; Flexner C; Sheiner LB; Rosenkranz SL; Segal Y; Aberg JA; Blaschke TF;
Clin Pharmacol Ther; 2003 May; 73(5):406-16. PubMed ID: 12732841
[TBL] [Abstract][Full Text] [Related]
9. Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS.
Klaus BD; Grodesky MJ
Nurse Pract; 1998 Feb; 23(2):102-4, 106. PubMed ID: 9513221
[No Abstract] [Full Text] [Related]
10. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.
Hugen PW; Verweij-van Wissen CP; Burger DM; Wuis EW; Koopmans PP; Hekster YA
J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):139-49. PubMed ID: 10360433
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS
Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366
[TBL] [Abstract][Full Text] [Related]
12. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
Stocker H; Herzmann C; Breske A; Kruse G; Berger M; Schulbin H; Hill A; Steinmüller J; Becker M; Arastéh K; Kurowski M
J Antimicrob Chemother; 2007 Mar; 59(3):560-4. PubMed ID: 17255144
[TBL] [Abstract][Full Text] [Related]
13. No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients.
Schippers EF; Hugen PW; den Hartigh J; Burger DM; Hoetelmans RM; Visser LG; Kroon FP
AIDS; 2000 Dec; 14(17):2794-5. PubMed ID: 11125902
[No Abstract] [Full Text] [Related]
14. Sildenafil plasma concentrations in two HIV patients with pulmonary hypertension treated with ritonavir-boosted protease inhibitors.
Chinello P; Cicalini S; Pichini S; Pacifici R; Tempestilli M; Petrosillo N
Curr HIV Res; 2012 Mar; 10(2):162-4. PubMed ID: 22329523
[TBL] [Abstract][Full Text] [Related]
15. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
[TBL] [Abstract][Full Text] [Related]
16. Investigation on interaction between tacrolimus and sildenafil in kidney-transplanted patients with erectile dysfunction.
Christ B; Brockmeier D; Hauck EW; Kamali-Ernst S
Int J Clin Pharmacol Ther; 2004 Mar; 42(3):149-56. PubMed ID: 15049434
[TBL] [Abstract][Full Text] [Related]
17. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
[TBL] [Abstract][Full Text] [Related]
18. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
Aarnoutse RE; Grintjes KJ; Telgt DS; Stek M; Hugen PW; Reiss P; Koopmans PP; Hekster YA; Burger DM
Clin Pharmacol Ther; 2002 Jan; 71(1):57-67. PubMed ID: 11823758
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
Kuschak D; Mauss S; Schmutz G; Gantke B
Clin Lab; 2001; 47(9-10):471-7. PubMed ID: 11596909
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
